Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment

New development in CAR-T cell therapy

(2017) Zhenguang Wang et al.   Journal of Hematology & Oncology

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer

(2016) Yu Cao et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

(2016) Gideon Gross et al.   Annual Review of Pharmacology and Toxicology

Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL

(2016) X. Wang et al.   BLOOD

PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

(2016) Elise A. Chong et al.   BLOOD

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

(2016) R. Gardner et al.   BLOOD

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

(2016) Kole T. Roybal et al.   CELL

CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells

(2016) Xiaojuan Liu et al.   CELL RESEARCH

Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

(2016) Hong Liu et al.   CLINICAL CANCER RESEARCH

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

(2016) Jiangtao Ren et al.   CLINICAL CANCER RESEARCH

Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells

(2016) Mark B. Geyer et al.   CYTOTHERAPY

A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells

(2016) Qing Ma et al.   CYTOTHERAPY

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy

(2016) Mark O'Hara et al.   Immunotherapy

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

(2016) Meenakshi Hegde et al.   JOURNAL OF CLINICAL INVESTIGATION

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

(2016) Marco Ruella et al.   JOURNAL OF CLINICAL INVESTIGATION

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

(2016) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors

(2016) Hiroki Torikai et al.   MOLECULAR THERAPY

Genome-editing Technologies for Gene and Cell Therapy

(2016) Morgan L Maeder et al.   MOLECULAR THERAPY

Superior Therapeutic Index in Lymphoma Therapy: CD30 + CD34 + Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack

(2016) Andreas A Hombach et al.   MOLECULAR THERAPY

Off-the-shelf CAR-T therapy induces remission in child with ALL

(2016) Mark Ratner   NATURE BIOTECHNOLOGY

Juno's wild ride

(2016) Laura DeFrancesco   NATURE BIOTECHNOLOGY

Prospects for gene-engineered T cell immunotherapy for solid cancers

(2016) Christopher A Klebanoff et al.   NATURE MEDICINE

Driving CAR T-cells forward

(2016) Hollie J. Jackson et al.   Nature Reviews Clinical Oncology

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Versatile strategy for controlling the specificity and activity of engineered T cells

(2016) Jennifer S. Y. Ma et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies

(2016) David T. Rodgers et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells

(2016) Yajing Zhang et al.   Science China-Life Sciences

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer

(2016) Kaichao Feng et al.   Science China-Life Sciences

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

(2016) Cameron J. Turtle et al.   Science Translational Medicine

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

(2016) Nathan Singh et al.   Science Translational Medicine

Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors

(2016) Daniel T. Harris et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

(2016) D. T. Teachey et al.   Cancer Discovery

Tales of Antigen Evasion from CAR Therapy

(2016) M. Sadelain   Cancer Immunology Research

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

(2016) E. Zah et al.   Cancer Immunology Research

Chimeric antigen receptor T-cell therapy for solid tumors

(2016) Kheng Newick et al.   Molecular Therapy-Oncolytics

Toxicity and management in CAR T-cell therapy

(2016) Challice L Bonifant et al.   Molecular Therapy-Oncolytics

Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds

(2016) Michael Kalos   Journal for ImmunoTherapy of Cancer

Design of chimeric antigen receptors with integrated controllable transient functions

(2016) Alexandre Juillerat et al.   Scientific Reports

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

CD19 chimeric antigen receptor T cell therapy for haematological malignancies

(2015) Sara Ghorashian et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells

(2015) Andrew G. Evans et al.   BRITISH JOURNAL OF HAEMATOLOGY

Shifting the Evolving CAR T Cell Platform into Higher Gear

(2015) Daniel R. Holohan et al.   CANCER CELL

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Moving from tinkering in the garage to assembly line production: the manufacture of genetically modified T cells expressing chimeric antigen receptors (CARs) comes on line

(2015) L J N Cooper   CANCER GENE THERAPY

Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers

(2015) Janos L. Tanyi et al.   CANCER RESEARCH

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

(2015) X. Liu et al.   CANCER RESEARCH

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

(2015) H. G. Caruso et al.   CANCER RESEARCH

Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

(2015) C. E. Brown et al.   CLINICAL CANCER RESEARCH

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

(2015) S. C. Katz et al.   CLINICAL CANCER RESEARCH

Paving the road ahead for CD19 CAR T-cell therapy

(2015) Anandani Nellan et al.   CURRENT OPINION IN HEMATOLOGY

ErbB-targeted CAR T-cell immunotherapy of cancer

(2015) Lynsey M Whilding et al.   Immunotherapy

CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?

(2015) Hollie J Pegram et al.   Immunotherapy

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

(2015) David M. Barrett et al.   JOURNAL OF IMMUNOLOGY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Novel immunotherapies in lymphoid malignancies

(2015) Connie Lee Batlevi et al.   Nature Reviews Clinical Oncology

The pharmacology of second-generation chimeric antigen receptors

(2015) Sjoukje J. C. van der Stegen et al.   NATURE REVIEWS DRUG DISCOVERY

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor

(2015) C.-Y. Wu et al.   SCIENCE

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Engineering CAR-T cells: Design concepts

(2015) Shivani Srivastava et al.   TRENDS IN IMMUNOLOGY

Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system

(2015) Yago Pico de Coaña et al.   TRENDS IN MOLECULAR MEDICINE

Overcoming Antigen Escape with CAR T-cell Therapy

(2015) H. J. Jackson et al.   Cancer Discovery

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis

(2015) Tengfei Zhang et al.   Oncotarget

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

(2015) Hanren Dai et al.   OncoImmunology

Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors

(2014) Saveria Pastore et al.   ARCHIVES OF TOXICOLOGY

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

CD28z CARs and Armored CARs

(2014) Hollie J. Pegram et al.   CANCER JOURNAL

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

(2014) Yao Wang et al.   CLINICAL IMMUNOLOGY

From the Mouse Cage to Human Therapy: A Personal Perspective of the Emergence of T-bodies/Chimeric Antigen Receptor T Cells

(2014) Zelig Eshhar   HUMAN GENE THERAPY

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

(2014) Saar Gill et al.   IMMUNOLOGICAL REVIEWS

Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy

(2014) B. Thaci et al.   NEURO-ONCOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor

(2014) Ge Zhang et al.   Scientific Reports

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

(2014) M. Hudecek et al.   Cancer Immunology Research

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

(2013) J. N. Kochenderfer et al.   BLOOD

Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells

(2013) Xiao-Jun Xu et al.   CANCER LETTERS

Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

(2013) M. Hudecek et al.   CLINICAL CANCER RESEARCH

Design and development of therapies using chimeric antigen receptor-expressing T cells

(2013) Gianpietro Dotti et al.   IMMUNOLOGICAL REVIEWS

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

(2013) Markus Chmielewski et al.   IMMUNOLOGICAL REVIEWS

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma

(2013) Bryan D. Choi et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

(2013) David S. Ritchie et al.   MOLECULAR THERAPY

Calling cells to arms

(2013) Emily Elert   NATURE

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

Multiplex Genome Engineering Using CRISPR/Cas Systems

(2013) L. Cong et al.   SCIENCE

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

(2013) L. R. Desnoyers et al.   Science Translational Medicine

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

(2013) G. L. Beatty et al.   Cancer Immunology Research

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

(2013) M. V. Maus et al.   Cancer Immunology Research

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

(2013) Zakaria Grada et al.   Molecular Therapy-Nucleic Acids

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

(2012) B. G. Till et al.   BLOOD

Abstract 3500: T cells redirected against HER2 for the adoptive immunotherapy for HER2-positive osteosarcoma

(2012) Nabil Ahmed et al.   CANCER RESEARCH

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Hodgkin lymphoma

(2012) Ralf Küppers et al.   JOURNAL OF CLINICAL INVESTIGATION

Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions

(2012) Kevin J. Curran et al.   JOURNAL OF GENE MEDICINE

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

Familial and Acquired Hemophagocytic Lymphohistiocytosis

(2011) G.E. Janka   Annual Review of Medicine

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

(2011) S. Terakura et al.   BLOOD

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells

(2011) David M. Barrett et al.   HUMAN GENE THERAPY

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

Chimeric Antigen Receptor–Modified T Cells in CLL

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

(2010) Michael C. Jensen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

(2010) C. H. J. Lamers et al.   BLOOD

Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice

(2010) X. Wang et al.   BLOOD

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

(2010) Y. Zhao et al.   CANCER RESEARCH

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen

(2010) S Peinert et al.   GENE THERAPY

Is It Safer CARs That We Need, or Safer Rules of the Road?

(2010) Richard P Junghans   MOLECULAR THERAPY

Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial

(2010) Renier Brentjens et al.   MOLECULAR THERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

(2010) Maria R Parkhurst et al.   MOLECULAR THERAPY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

(2009) A. Di Stasi et al.   BLOOD

Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication

(2009) Xiao-Song Zhong et al.   MOLECULAR THERAPY

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD

EGF receptor variant III as a target antigen for tumor immunotherapy

(2008) Gordon Li et al.   Expert Review of Vaccines

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE